Research ExplorerPublicationsCharacteristics and Outcomes of Patients Screened for Transc...

Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry

Standard

Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry. / Ali, Walid Ben; Ludwig, Sebastian; Duncan, Alison; Weimann, Jessica; Nickenig, Georg; Tanaka, Tetsu; Coisne, Augustin; Vincentelli, Andre; Makkar, Raj; Webb, John G; Akodad, Mariama; Muller, David W M; Praz, Fabien; Wild, Mirjam G; Hausleiter, Jörg; Goel, Sachin S; von Ballmoos, Moritz Wyler; Denti, Paolo; Chehab, Omar; Redwood, Simon; Dahle, Gry; Baldus, Stephan; Adam, Matti; Ruge, Hendrik; Lange, Rüderiger; Kaneko, Tsuyoshi; Leroux, Lionel; Dumonteil, Nicolas; Tchetche, Didier; Treede, Hendrik; Flagiello, Michele; Obadia, Jean-Francois; Walther, Thomas; Taramasso, Maurizio; Søndergaard, Lars; Bleiziffer, Sabine; Rudolph, Tanja K; Fam, Neil; Kempfert, Joerg; Granada, Juan F; Tang, Gilbert H L; von Bardeleben, Ralph Stephan; Conradi, Lenard; Modine, Thomas; CHOICE-MI Investigators.

In: EUR J HEART FAIL, Vol. 24, No. 5, 05.2022, p. 887-898.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ali, WB, Ludwig, S, Duncan, A, Weimann, J, Nickenig, G, Tanaka, T, Coisne, A, Vincentelli, A, Makkar, R, Webb, JG, Akodad, M, Muller, DWM, Praz, F, Wild, MG, Hausleiter, J, Goel, SS, von Ballmoos, MW, Denti, P, Chehab, O, Redwood, S, Dahle, G, Baldus, S, Adam, M, Ruge, H, Lange, R, Kaneko, T, Leroux, L, Dumonteil, N, Tchetche, D, Treede, H, Flagiello, M, Obadia, J-F, Walther, T, Taramasso, M, Søndergaard, L, Bleiziffer, S, Rudolph, TK, Fam, N, Kempfert, J, Granada, JF, Tang, GHL, von Bardeleben, RS, Conradi, L, Modine, T & CHOICE-MI Investigators 2022, 'Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry', EUR J HEART FAIL, vol. 24, no. 5, pp. 887-898. https://doi.org/10.1002/ejhf.2492

APA

Ali, W. B., Ludwig, S., Duncan, A., Weimann, J., Nickenig, G., Tanaka, T., Coisne, A., Vincentelli, A., Makkar, R., Webb, J. G., Akodad, M., Muller, D. W. M., Praz, F., Wild, M. G., Hausleiter, J., Goel, S. S., von Ballmoos, M. W., Denti, P., Chehab, O., ... CHOICE-MI Investigators (2022). Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry. EUR J HEART FAIL, 24(5), 887-898. https://doi.org/10.1002/ejhf.2492

Vancouver

Ali WB, Ludwig S, Duncan A, Weimann J, Nickenig G, Tanaka T et al. Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry. EUR J HEART FAIL. 2022 May;24(5):887-898. https://doi.org/10.1002/ejhf.2492

Bibtex

@article{6c1d017eb7e44ec298fd965b951e4189,
title = "Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry",
abstract = "AIMS: Transcatheter mitral valve implantation (TMVI) represents a novel treatment option for patients with mitral regurgitation (MR) unsuitable for established therapies. The CHOICE-MI registry aimed to investigate outcomes of patients undergoing screening for TMVI.METHODS AND RESULTS: From May 2014 to March 2021, patients with MR considered suboptimal candidates for transcatheter edge-to-edge repair (TEER) and at high risk for mitral valve surgery underwent TMVI screening at 26 centres. Characteristics and outcomes were investigated for patients undergoing TMVI and for TMVI-ineligible patients referred to bailout-TEER, high-risk surgery or medical therapy (MT). The primary composite endpoint was all-cause mortality or heart failure hospitalization after 1 year. Among 746 patients included (78.5 years, interquartile range [IQR] 72.0-83.0, EuroSCORE II 4.7% [IQR 2.7-9.7]), 229 patients (30.7%) underwent TMVI with 10 different dedicated devices. At 1 year, residual MR ≤1+ was present in 95.2% and the primary endpoint occurred in 39.2% of patients treated with TMVI. In TMVI-ineligible patients (n = 517, 69.3%), rates of residual MR ≤1+ were 37.2%, 100.0% and 2.4% after bailout-TEER, high-risk surgery and MT, respectively. The primary endpoint at 1 year occurred in 28.8% of patients referred to bailout-TEER, in 42.9% of patients undergoing high-risk surgery and in 47.9% of patients remaining on MT.CONCLUSION: This registry included the largest number of patients treated with TMVI to date. TMVI with 10 dedicated devices resulted in predictable MR elimination and sustained functional improvement at 1 year. In TMVI-ineligible patients, bailout-TEER and high-risk surgery represented reasonable alternatives, while MT was associated with poor clinical and functional outcomes.",
author = "Ali, {Walid Ben} and Sebastian Ludwig and Alison Duncan and Jessica Weimann and Georg Nickenig and Tetsu Tanaka and Augustin Coisne and Andre Vincentelli and Raj Makkar and Webb, {John G} and Mariama Akodad and Muller, {David W M} and Fabien Praz and Wild, {Mirjam G} and J{\"o}rg Hausleiter and Goel, {Sachin S} and {von Ballmoos}, {Moritz Wyler} and Paolo Denti and Omar Chehab and Simon Redwood and Gry Dahle and Stephan Baldus and Matti Adam and Hendrik Ruge and R{\"u}deriger Lange and Tsuyoshi Kaneko and Lionel Leroux and Nicolas Dumonteil and Didier Tchetche and Hendrik Treede and Michele Flagiello and Jean-Francois Obadia and Thomas Walther and Maurizio Taramasso and Lars S{\o}ndergaard and Sabine Bleiziffer and Rudolph, {Tanja K} and Neil Fam and Joerg Kempfert and Granada, {Juan F} and Tang, {Gilbert H L} and {von Bardeleben}, {Ralph Stephan} and Lenard Conradi and Thomas Modine and {CHOICE-MI Investigators}",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
month = may,
doi = "10.1002/ejhf.2492",
language = "English",
volume = "24",
pages = "887--898",
journal = "EUR J HEART FAIL",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Characteristics and Outcomes of Patients Screened for Transcatheter Mitral Valve Implantation: 1-Year Results from the CHOICE-MI Registry

AU - Ali, Walid Ben

AU - Ludwig, Sebastian

AU - Duncan, Alison

AU - Weimann, Jessica

AU - Nickenig, Georg

AU - Tanaka, Tetsu

AU - Coisne, Augustin

AU - Vincentelli, Andre

AU - Makkar, Raj

AU - Webb, John G

AU - Akodad, Mariama

AU - Muller, David W M

AU - Praz, Fabien

AU - Wild, Mirjam G

AU - Hausleiter, Jörg

AU - Goel, Sachin S

AU - von Ballmoos, Moritz Wyler

AU - Denti, Paolo

AU - Chehab, Omar

AU - Redwood, Simon

AU - Dahle, Gry

AU - Baldus, Stephan

AU - Adam, Matti

AU - Ruge, Hendrik

AU - Lange, Rüderiger

AU - Kaneko, Tsuyoshi

AU - Leroux, Lionel

AU - Dumonteil, Nicolas

AU - Tchetche, Didier

AU - Treede, Hendrik

AU - Flagiello, Michele

AU - Obadia, Jean-Francois

AU - Walther, Thomas

AU - Taramasso, Maurizio

AU - Søndergaard, Lars

AU - Bleiziffer, Sabine

AU - Rudolph, Tanja K

AU - Fam, Neil

AU - Kempfert, Joerg

AU - Granada, Juan F

AU - Tang, Gilbert H L

AU - von Bardeleben, Ralph Stephan

AU - Conradi, Lenard

AU - Modine, Thomas

AU - CHOICE-MI Investigators

N1 - This article is protected by copyright. All rights reserved.

PY - 2022/5

Y1 - 2022/5

N2 - AIMS: Transcatheter mitral valve implantation (TMVI) represents a novel treatment option for patients with mitral regurgitation (MR) unsuitable for established therapies. The CHOICE-MI registry aimed to investigate outcomes of patients undergoing screening for TMVI.METHODS AND RESULTS: From May 2014 to March 2021, patients with MR considered suboptimal candidates for transcatheter edge-to-edge repair (TEER) and at high risk for mitral valve surgery underwent TMVI screening at 26 centres. Characteristics and outcomes were investigated for patients undergoing TMVI and for TMVI-ineligible patients referred to bailout-TEER, high-risk surgery or medical therapy (MT). The primary composite endpoint was all-cause mortality or heart failure hospitalization after 1 year. Among 746 patients included (78.5 years, interquartile range [IQR] 72.0-83.0, EuroSCORE II 4.7% [IQR 2.7-9.7]), 229 patients (30.7%) underwent TMVI with 10 different dedicated devices. At 1 year, residual MR ≤1+ was present in 95.2% and the primary endpoint occurred in 39.2% of patients treated with TMVI. In TMVI-ineligible patients (n = 517, 69.3%), rates of residual MR ≤1+ were 37.2%, 100.0% and 2.4% after bailout-TEER, high-risk surgery and MT, respectively. The primary endpoint at 1 year occurred in 28.8% of patients referred to bailout-TEER, in 42.9% of patients undergoing high-risk surgery and in 47.9% of patients remaining on MT.CONCLUSION: This registry included the largest number of patients treated with TMVI to date. TMVI with 10 dedicated devices resulted in predictable MR elimination and sustained functional improvement at 1 year. In TMVI-ineligible patients, bailout-TEER and high-risk surgery represented reasonable alternatives, while MT was associated with poor clinical and functional outcomes.

AB - AIMS: Transcatheter mitral valve implantation (TMVI) represents a novel treatment option for patients with mitral regurgitation (MR) unsuitable for established therapies. The CHOICE-MI registry aimed to investigate outcomes of patients undergoing screening for TMVI.METHODS AND RESULTS: From May 2014 to March 2021, patients with MR considered suboptimal candidates for transcatheter edge-to-edge repair (TEER) and at high risk for mitral valve surgery underwent TMVI screening at 26 centres. Characteristics and outcomes were investigated for patients undergoing TMVI and for TMVI-ineligible patients referred to bailout-TEER, high-risk surgery or medical therapy (MT). The primary composite endpoint was all-cause mortality or heart failure hospitalization after 1 year. Among 746 patients included (78.5 years, interquartile range [IQR] 72.0-83.0, EuroSCORE II 4.7% [IQR 2.7-9.7]), 229 patients (30.7%) underwent TMVI with 10 different dedicated devices. At 1 year, residual MR ≤1+ was present in 95.2% and the primary endpoint occurred in 39.2% of patients treated with TMVI. In TMVI-ineligible patients (n = 517, 69.3%), rates of residual MR ≤1+ were 37.2%, 100.0% and 2.4% after bailout-TEER, high-risk surgery and MT, respectively. The primary endpoint at 1 year occurred in 28.8% of patients referred to bailout-TEER, in 42.9% of patients undergoing high-risk surgery and in 47.9% of patients remaining on MT.CONCLUSION: This registry included the largest number of patients treated with TMVI to date. TMVI with 10 dedicated devices resulted in predictable MR elimination and sustained functional improvement at 1 year. In TMVI-ineligible patients, bailout-TEER and high-risk surgery represented reasonable alternatives, while MT was associated with poor clinical and functional outcomes.

U2 - 10.1002/ejhf.2492

DO - 10.1002/ejhf.2492

M3 - SCORING: Journal article

C2 - 35338542

VL - 24

SP - 887

EP - 898

JO - EUR J HEART FAIL

JF - EUR J HEART FAIL

SN - 1388-9842

IS - 5

ER -